Live Breaking News & Updates on Her2 negative

Stay informed with the latest breaking news from Her2 negative on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Her2 negative and stay connected to the pulse of your community

NBC Nightly News With Lester Holt

record summer travel and not enough planes. why some airline experts say the price of your ticket could be about to go up. and the caught-on-camera moment. this man fighting back against an alleged car thief. what he's telling our reporter about that night. tive breast cancer is overwhelming. but i never just found my way; i made it. and did all i could to prevent recurrence. verzenio reduces the risk of recurrence of hr-positive, her2-negative, node-positive, early breast cancer with a high chance of returning as determined by your doctor when added to hormone therapy. diarrhea is common, may be severe, or cause dehydration or infection. at the first sign, call your doctor, start an anti-diarrheal , and drink fluids. before taking verzenio, tell your doctor about any fever, chills, or other signs of infection. verzenio may cause low white blood cell counts, which may cause serious infection that can lead to death. life-threatening lung inflammation can occur. tell your doctor about any new or worsening trouble breathing, cough, or chest pain. serious liver problems can happen. symptoms include fatigue, appetite loss, stomach pain, and bleeding or bruising. blood clots that can lead to death have occurred.

Reporter , Planes , Price , Car-thief , Man , Record-summer-travel , Ticket , Airline-experts , All , Way , Doctor , Risk

The Five

slowest," this is "the fastest." >> tyrus: i was murdock, middle-of-the-road, but also -- that's a lot. >> harold: emily c and harold, we were at the top of the class. >> tyrus: are you saying you didn't get by on merit? you got your deis? jesse and i, we earned our stripes. >> harold: ""fan mail friday"" is up next. ♪ ♪ moving forward with node-positive breast cancer is overwhelming. but i never just found my way; i made it. and did all i could to prevent recurrence. verzenio reduces the risk of recurrence of hr-positive, her2-negative, node-positive, early breast cancer with a high chance of returning as determined by your doctor when added to hormone therapy. diarrhea is common, may be severe, or cause dehydration or infection.

Harold-ford-jr- , Emily-c , Tyrus , Lot , Harold , Road , Top , Class , Murdock , Jesse-watters , Didn-t , Stripes

Astellas wins first approval of Vyloy in gastric cancer in Japan

Japan’s Ministry of Health, Labor and Welfare approved Astellas Pharma Inc.’s Vyloy (zolbetuximab) to treat a type of advanced gastric cancer on March 26, making it the first anti-claudin 18.2 monoclonal antibody to gain regulatory clearance worldwide.

Japan , Astellas-pharma-inc , Japan-ministry-of-health , Astellas-pharma , Astellas-pharma-inc- , Vyloy , Zolbetuximab , Gastric-cancer , Claudin18-2 , Cldn18-2 , Her2-negative

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

William-gradishar , Gregory-vidal , Rena-callahan , Mabel-mardones , Peer-exchange , European-society-for-medical-oncology-congress , Medical-oncology-congress , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances

Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

William-gradishar , Mabel-mardones , Rena-callahan , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Rena-callahan , William-gradishar , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

FDA Fast Tracks ARV-471 for Metastatic Breast Cancer

The Food and Drug Administration granted a Fast Track designation to the novel drug, ARV-471 for patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer.

Roger-dansey , John-houston , Drug-administration , Pfizer , Fast-track , News , Breast-cancer , Fda , Er-positive , Her2-negative , Metastatic-breast-cancer ,

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

William-gradishar , Rena-callahan , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

Experts discuss how they determine whether a patient with metastatic breast cancer is a candidate for treatment with elacestrant based on FDA approved indication, NCCN guidelines, and the results of ESR1 mutation and resistance marker testing. Participants also discuss how they determine treatment failure or resistance.

Breast-cancer , Clinical-guidelines , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive , Her2-negative , Selective-estrogen-receptor-degrader

Gutfeld

her2-negative, node-positive, early breast cancer with a high chance of returning, as determined by your doctor when added to hormone therapy. hormone therapy works outside the cell... while verzenio works inside to help stop the growth of cancer cells. diarrhea is common, may be severe, or cause dehydration or infection. at the first sign, call your doctor, start an antidiarrheal, and drink fluids. before taking verzenio, tell your doctor about any fever, chills, or other signs of infection. verzenio may cause low white blood cell counts, which may cause serious infection that can lead to death. life-threatening lung inflammation can occur. tell your doctor about any new or worsening trouble breathing, cough, or chest pain. serious liver problems can happen. symptoms include fatigue, appetite loss, stomach pain, and bleeding or bruising. blood clots that can lead to death have occurred. tell your doctor if you have pain or swelling in your arms or legs, shortness of breath, chest pain, and rapid breathing or heart rate, or if you are nursing, pregnant, or plan to be. i'm making my own way forward. ask your doctor about everyday verzenio. we're travelling all across america, talking to people about their hearts. wh-who wants to talk about their heart! how's the heart? how's your heart?

Doctor , Chance , Hormone-therapy , Positive , Breast-cancer , Cell , Cancer-cells , Diarrhea , Her2-negative , Growth , Verzenio-works-inside , Infection